Amidst cries from Congress and the public to act more quickly to authorize COVID-19 vaccines in children under the age of five, the US Food and Drug Administration is ready to move up tentatively scheduled dates for its Vaccines and Related Biological Products Advisory Committee to consider authorization of Pfizer Inc./BioNTech SE and Moderna, Inc.’s vaccines in the youngest populations as soon as it receives their complete submissions.
“I fully expect that we’ll have the data in June or by June ready for review” and whichever of these...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?